The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
SOHO invites delegates and attendees to submit an abstract for a poster or oral presentation during the Fourteenth Annual Meeting of the Society of Hematologic
Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm, according to the results of a phase 2 trial presented during the 67th American Society of Hematology Annual Meeting and Exposition.
The United States Food and Drug Administration (FDA) has signed off on a new, larger vial size for Nelarabine Injection for adult and pediatric patients with T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL).
A Letter to the Editor published in the American Journal of Hematology by Rong Wang, PhD, of Yale University, and colleagues is the “first study” to show smoldering multiple myeloma (SMM) incidence in the United States using cancer registry da
The first session of the Community Oncology Brown Bag Series hosted by SOHO Insider was held on January 20, 2026, and featured guest speaker Manali Kamdar, MD, director of the Clinical Lymphoma Program at the University of Colorado. Dr. Kamdar discussed “Expanding access to CAR T-cell therapy outside academic centers.”
To access the SOHO Career Center click the following link.
